Understand total testosterone reference ranges, guideline thresholds, symptom assessment and the role of repeat testing, SHBG and free testosterone.
Total testosterone (TT) is the testosterone concentration measured in serum from a blood sample. It is usually the starting laboratory measurement when clinicians assess possible testosterone deficiency, as reflected in European Association of Urology (EAU) guidance.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret personal results and make diagnostic or treatment decisions.
Start with the reference interval printed beside the result. That interval describes how the measured concentration compares with values in the population used to establish the laboratory's range. It is a comparison framework rather than a description of symptoms or a personal treatment goal.
The Endocrine Society calls for accurate assays and rigorously derived reference ranges. An assay is the laboratory method used to measure testosterone. Both the method and the population behind the interval matter when interpreting where a result falls.
A testosterone number should be read together with its units and the reporting laboratory's interval. Taking the number out of that setting removes information needed to understand the laboratory's interpretation.
Biologically, TT describes a measured concentration in serum. The reference interval places that concentration within a comparison framework. It does not directly measure whether a man's symptoms are caused by testosterone deficiency.
This distinction matters when a report marks a value as low. The flag describes its position relative to the laboratory's interval. The clinical meaning of that finding requires a separate assessment.
A reference interval and a clinical decision threshold serve different purposes. The former describes a laboratory comparison population. The latter helps clinicians apply guidance in a defined clinical setting.
The research illustrates why these should remain separate:
These figures are not the lower and upper boundaries of one normal range. Combining them into a new interval would misrepresent the recommendations. Each belongs to the clinical circumstances described by its source.
The laboratory's full reference interval, including its upper boundary, should remain attached to that particular report. Neither of these lower thresholds supplies a universal reference interval for every adult man.
When reviewing results from different laboratories, compare more than the headline number. The useful details include:
The Endocrine Society's emphasis on accurate assays supports this approach. A result from another laboratory should not automatically be treated as interchangeable simply because both reports say “total testosterone.”
For more background on interpreting the measurement itself, see Testostra's guide to putting a total testosterone value in context.
The Endocrine Society recommends diagnosing hypogonadism only when compatible symptoms or signs accompany unequivocally and consistently low testosterone. In other words, the diagnosis joins clinical findings with laboratory evidence. Neither part replaces the other.
For adult men, the EAU describes sexual symptoms as the most specific symptoms associated with late-onset hypogonadism. That makes sexual concerns relevant to the clinical history. It does not make those concerns diagnostic by themselves.
A useful discussion describes the symptoms rather than starting with a conclusion about their cause. Points worth bringing into that conversation include:
This keeps the discussion focused on the clinical question: whether the reported symptoms and the biochemical findings fit together. It also gives the clinician something more useful than a request to interpret an isolated laboratory flag.
Testostra's explanation of why symptoms and blood testing belong together provides further context for that distinction.
The Endocrine Society recommends against routine population screening for hypogonadism in men without symptoms. An unexpected result from screening should therefore not be treated as though it already establishes a symptomatic clinical condition.
For a man without symptoms, the appropriate conversation includes why testing was performed and what question the result is meant to answer. For a man with symptoms, the conversation includes whether the findings meet the clinical criteria for further evaluation.
An above-range result raises a separate question. Deficiency criteria should not be reversed to assume a matching symptom pattern for high testosterone.
The guidance identifies several kinds of context that deserve attention: morning collection, fasting status and conditions associated with altered SHBG. These are not interchangeable. Collection conditions concern how the sample is obtained, while SHBG-related physiology concerns how the hormone results may need to be interpreted.
The Endocrine Society recommends confirming a suspected diagnosis with repeat morning, fasting TT measurements. The EAU also recommends morning, fasting testing with a reliable assay.
These recommendations establish the testing conditions used in the diagnostic assessment. They should not be read as instructions for producing a preferred number. The practical question is whether the measurement is repeatable under the conditions recommended by the relevant guidance.
When reviewing an existing report, the collection time and whether the sample was fasting are useful details for the clinician. For a planned test, the clinician or laboratory can explain the applicable collection instructions.
The EAU recommends repeating the measurement on at least two separate occasions when TT is below 12 nmol/L before testosterone therapy is started. This is a confirmation requirement within its guidance, not a direction to begin treatment after a particular result.
The physician discussion can therefore focus on whether the available measurements meet the relevant testing conditions. Keeping the original reports available preserves the units and reference intervals alongside each result.
Repeat testing addresses the consistency of the biochemical finding. The symptom assessment addresses the clinical finding. Those are complementary parts of the evaluation rather than competing explanations.
The EAU recommends considering SHBG measurement and calculated free testosterone when conditions associated with altered SHBG are present. This is the physiological context in which TT may need complementary assessment.
The useful question is whether such a condition is relevant to the individual evaluation. It is not an assumption that every man needs an expanded hormone panel or that TT has no value.
For background on how these measurements relate, read about the role of hormone-binding proteins in a testosterone panel.
A recommendation for a fasting sample is a testing recommendation. It does not establish that a particular diet will correct a low result. Likewise, a recommendation to assess SHBG does not identify a particular food or supplement as the explanation for an individual's hormone findings.
Keeping these distinctions clear helps prevent a laboratory interpretation question from turning into an unsupported lifestyle prescription. Personal decisions about further investigation belong with the clinician reviewing the full clinical picture.
Ask your physician: “Which laboratory interval and guideline apply to my result, do my symptoms fit the clinical picture, should morning fasting TT be repeated and would SHBG or calculated free testosterone help?”
A total testosterone result may still leave a binding-protein question open, so Testostra places related biomarkers in clinical context. For men unsure how SHBG relates to total and free testosterone, its evidence-led explanations support a more informed discussion of laboratory results while keeping personal diagnosis and treatment outside its educational role.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra